Hi suny!
“Why would they be participating in the Emerging Growth Conference if there was going to be a buyout”
That’s a good question. I thought of that before posting, and considered that perhaps immunome has already struck a deal with ENZC, and it decided to include ENZC or to present alongside ENZC.
Could just be they have a non-exclusive licensing agreement.
If ENZC has already partnered with immunome, or licensed to immunome, either scenario would make sense to present at the same conference. The goal of the conference is to present and communicate new products, services and other major announcements, so wether or not ENZC inked a deal or a few deals, or no deal, participating seems beneficial imo.
My thoughts only, nothing concrete to back them up, but I also thought “what if one or several of the big pharma cos are working with immunome . Maybe there is a package deal buyout or multi-licensing opportunity using an immunome/ENZC cocktail.
It could be none of these things, but worth considering imo given the various hashtags Dr. Chandra has included in his tweets.
The way I see it, every pharmaceutical company should be looking for partnerships to do whatever is necessary to nip this thing ASAP! When you have every person on planet earth needing the same thing at the same time there is no room or time to monopolize. Hopefully, that’s immunome and ENZC’s aim.
Thanks for raising the question. Next few weeks will be interesting and hopefully exciting!
Wishing you much luck!
News 
Market Data 
Discover 
AI
